Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Idhifa (enasidenib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Agios Pharma, BMS, Royalty, Servier

Drug class:

IDH2 inhibitor

Related drugs:

‹

›

IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	enasidenib Sensitive: A1 - Approval enasidenib Sensitive : A1	enasidenib Sensitive: A1 - Approval enasidenib Sensitive : A1
IDH2 R172	Acute Myelogenous Leukemia	IDH2 R172	Acute Myelogenous Leukemia	enasidenib Sensitive: B - Late Trials enasidenib Sensitive : B	enasidenib Sensitive: B - Late Trials enasidenib Sensitive : B
IDH2 mutation	Acute Lymphocytic Leukemia	IDH2 mutation	Acute Lymphocytic Leukemia	enasidenib Sensitive: B - Late Trials enasidenib Sensitive : B	enasidenib Sensitive: B - Late Trials enasidenib Sensitive : B
IDH2 R140	Acute Myelogenous Leukemia	IDH2 R140	Acute Myelogenous Leukemia	enasidenib Sensitive: C2 – Inclusion Criteria enasidenib Sensitive : C2	enasidenib Sensitive: C2 – Inclusion Criteria enasidenib Sensitive : C2
IDH2 mutation	Myelodysplastic Syndrome	IDH2 mutation	Myelodysplastic Syndrome	enasidenib Sensitive: C2 – Inclusion Criteria enasidenib Sensitive : C2	enasidenib Sensitive: C2 – Inclusion Criteria enasidenib Sensitive : C2
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	venetoclax + enasidenib Sensitive: C3 – Early Trials venetoclax + enasidenib Sensitive : C3	venetoclax + enasidenib Sensitive: C3 – Early Trials venetoclax + enasidenib Sensitive : C3
MYC overexpression + IDH2 mutation	Acute Myelogenous Leukemia	MYC overexpression + IDH2 mutation	Acute Myelogenous Leukemia	enasidenib Resistant: C3 – Early Trials enasidenib Resistant : C3	enasidenib Resistant: C3 – Early Trials enasidenib Resistant : C3
MYC overexpression + IDH1 mutation	Acute Myelogenous Leukemia	MYC overexpression + IDH1 mutation	Acute Myelogenous Leukemia	enasidenib Resistant: C3 – Early Trials enasidenib Resistant : C3	enasidenib Resistant: C3 – Early Trials enasidenib Resistant : C3
IDH2 R140Q	Acute Myelogenous Leukemia	IDH2 R140Q	Acute Myelogenous Leukemia	venetoclax + enasidenib Sensitive: C3 – Early Trials venetoclax + enasidenib Sensitive : C3	venetoclax + enasidenib Sensitive: C3 – Early Trials venetoclax + enasidenib Sensitive : C3
IDH2 R172K	Acute Myelogenous Leukemia	IDH2 R172K	Acute Myelogenous Leukemia	venetoclax + enasidenib Sensitive: C3 – Early Trials venetoclax + enasidenib Sensitive : C3	venetoclax + enasidenib Sensitive: C3 – Early Trials venetoclax + enasidenib Sensitive : C3
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	venetoclax + enasidenib Sensitive: C3 – Early Trials venetoclax + enasidenib Sensitive : C3	venetoclax + enasidenib Sensitive: C3 – Early Trials venetoclax + enasidenib Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	venetoclax + enasidenib + decitabine/cedazuridine Sensitive: C3 – Early Trials venetoclax + enasidenib + decitabine / cedazuridine Sensitive : C3	venetoclax + enasidenib + decitabine/cedazuridine Sensitive: C3 – Early Trials venetoclax + enasidenib + decitabine / cedazuridine Sensitive : C3
IDH2 mutation	Hematological Malignancies	IDH2 mutation	Hematological Malignancies	venetoclax + enasidenib Sensitive: C3 – Early Trials venetoclax + enasidenib Sensitive : C3	venetoclax + enasidenib Sensitive: C3 – Early Trials venetoclax + enasidenib Sensitive : C3
IDH2 R140Q + NPM1 mutation	Acute Myelogenous Leukemia	IDH2 R140Q + NPM1 mutation	Acute Myelogenous Leukemia	venetoclax + enasidenib Sensitive: D – Preclinical venetoclax + enasidenib Sensitive : D	venetoclax + enasidenib Sensitive: D – Preclinical venetoclax + enasidenib Sensitive : D
IDH2 R140Q	Acute Myelogenous Leukemia	IDH2 R140Q	Acute Myelogenous Leukemia	enasidenib Sensitive: D – Preclinical enasidenib Sensitive : D	enasidenib Sensitive: D – Preclinical enasidenib Sensitive : D
IDH2 R172G	Sarcoma	IDH2 R172G	Sarcoma	enasidenib Sensitive: D – Preclinical enasidenib Sensitive : D	enasidenib Sensitive: D – Preclinical enasidenib Sensitive : D